Spots Global Cancer Trial Database for LY3214996 +/- HCQ in Pancreatic Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: LY3214996 +/- HCQ in Pancreatic Cancer

Official Title: Phase II Trial of ERK Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic Cancer

Study ID: NCT04386057

Conditions

Pancreatic Cancer

Advanced Cancer

Interventions

Hydroxychloroquine Sulfate

LY3214996

Study Description

Brief Summary: This study is evaluating the safety and efficacy of combining the study drug LY3214996 with hydroxychloroquine sulfate (HCQ) in patients with advanced pancreatic cancer.

Detailed Description: * This is an open label, randomized, two arm, phase II with safety lead- in study exploring the anti-tumor activity of the extracellular signal-regulated kinase (ERK) inhibitor LY3214996 with and without hydroxychloroquine (HCQ) in patients with advanced pancreatic cancer. * The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits. * The safety lead-in will test the safety of a combination of investigational drugs and also try to define appropriate dosage. The names of the study drugs involved in this study are: * LY3214996 * Hydroxychloroquine Sulfate (HCQ) * Following completion of a brief combination treatment safety lead-in cohort, participants will be randomized 1:1 for enrollment to one of two treatment arms: * Arm 1: receiving combination treatment with LY3214996 and HCQ * Arm 2: receiving monotherapy treatment with LY3214996 It is expected that about 52 people will take part in this research study The U.S. Food and Drug Administration (FDA) has not approved LY3214996 as a treatment for any disease. The U.S. Food and Drug Administration (FDA) has not approved HCQ for your specific disease but it has been approved for other uses.